Pharming Group
Pharming Group N.V. is a Dutch commercial-stage biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare and ultra-rare immunological and genetic diseases, with two approved products: RUCONEST for hereditary angioedema and Joenja for APDS.
- Company typePublic
- Founded1988
- HeadquartersLeiden, Netherlands
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Pharming Group firmographics
Firmographics- Name
- Pharming Group
- Legal name
- Pharming Group N.V.
- Website
- https://pharming.com
- Company type
- Public
- Founded year
- 1988
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Pharming Group N.V. is a Dutch commercial-stage biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare and ultra-rare immunological and genetic diseases, with two approved products: RUCONEST for hereditary angioedema and Joenja for APDS.
- Ownership category
- akta.pro rank
Pharming Group industry classification
Industry- Product category
- Rare disease biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
- akta.pro secondary industries
- Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
Keywords
Where Pharming Group is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices4 records
Markets served
Pharming Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- RUCONEST Product Sales: RUCONEST is the company's legacy product for acute hereditary angioedema (HAE) attacks, generating record sales. The product is commercialized directly in the US, EU, and UK through Pharming's own sales organization and through distribution networks internationally. Revenue from RUCONEST reached US$317.9 million in FY2025.
- Joenja Product Sales: Joenja (leniolisib) is the company's newer growth driver for APDS, approved in the US, UK, Japan, Australia, Israel, and now EU. Revenue from Joenja reached US$58.2 million in FY2025 and US$14.1 million in Q1 2026.
- Licensing and Royalty Revenue: Pharming receives licensing fees and royalties from commercialization partners including OrphanPacific for Japan and NewBridge Pharmaceuticals for Middle East and North Africa.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Pharming Group product offering
Product offeringCore offering
Pharming develops, manufactures, and commercializes protein replacement therapies and precision medicines for rare and ultra-rare immunological and genetic diseases. Its two commercial products are RUCONEST, a recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks, and Joenja (leniolisib), an oral PI3K delta inhibitor for activated PI3K delta syndrome (APDS), with a pipeline extending into primary mitochondrial disease (napazimone/KL1333) and gene therapy for HAE (OTL-105).
Product overview
Pharming Group is an integrated biotechnology company with two commercial products: RUCONEST® (a recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks) and Joenja® (leniolisib, a PI3Kδ inhibitor for APDS). The company has an advancing pipeline including napazimone (KL1333) for primary mitochondrial diseases and leniolisib expansion into CVID, acquired through the Abliva AB acquisition. The portfolio is focused on rare and ultra-rare immunological and genetic diseases.
Differentiator
Problem solved
Functional benefit
Brands
- RUCONEST: Recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy for acute hereditary angioedema (HAE) attacks
- Joenja
Products and services
- RUCONEST Recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy indicated for the treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents. It is the first and only plasma-free rhC1INH protein replacement therapy, replacing deficient C1-INH to downregulate the complement and contact cascades that drive acute swelling episodes.
- Joenja (leniolisib) Oral phosphoinositide 3-kinase delta (PI3K delta) inhibitor indicated for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency caused by genetic mutations in the PI3K delta pathway. Joenja targets the underlying disease driver of APDS to reduce immune dysregulation and prevent complications such as recurrent infections and lymphoproliferation. Worldwide rights were licensed in from Novartis in 2019.
- Napazimone (KL1333) Investigational compound for the treatment of primary mitochondrial diseases (PMD), currently in the pivotal FALCON trial phase. Acquired through the February 2025 Abliva AB acquisition as a core mitochondrial medicine asset.
- Leniolisib (Phase II expansion) PI3K delta inhibitor in Phase II clinical trials as a pipeline expansion of leniolisib into Common Variable Immunodeficiency (CVID) and other primary immunodeficiencies beyond APDS.
- OTL-105 Investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), developed in collaboration with Orchard Therapeutics under a strategic research, development, manufacturing, and commercialization agreement.
Quantifiable outcome
- Phase II/III trial met both primary endpoints with statistically significant improvements in immune markers in 31 APDS patients
- +2 more outcomes
Companies that use Pharming Group
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Pharming Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Pharming Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, regional, pipeline and market development.
- OrphanPacific, Inc.coreOrphanPacific commercializes Joenja (leniolisib) in Japan under a licensing agreement. Following Japan's approval of Joenja for APDS in patients aged 4 years and older, OrphanPacific handles commercialization including National Health Insurance drug pricing discussions. This is a key partnership for Pharming's expansion into the Japanese market.
- SanoficoreSanofi and Pharming renewed their strategic manufacturing partnership agreement. Sanofi provides manufacturing capabilities for Pharming's products, including RUCONEST. This partnership ensures reliable supply chain and manufacturing capacity for the company's commercial products.
- NewBridge PharmaceuticalsregionalNewBridge Pharmaceuticals commercializes RUCONEST in the Middle East and North Africa region. This partnership extends Pharming's geographic reach into MEA markets where the company does not maintain direct commercial operations.
- Orchard TherapeuticspipelineStrategic collaboration to research, develop, manufacture, and commercialize OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The collaboration combines Orchard Therapeutics' gene therapy expertise with Pharming's rare disease commercial infrastructure.
- Invitae Corporationmarket developmentPharming collaborated with Invitae to launch the navigateAPDS genetic testing program, helping patients get diagnosed with APDS. The program provides genetic testing to identify patients with the rare immunodeficiency, supporting disease awareness and patient identification for Joenja treatment.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Pharming Group competitors and assessment
Company assessmentDirect peers
- Swedish Orphan Biovitrum (Sobi): Sobi is a Sweden-based rare-disease biopharmaceutical company with overlapping HAE franchise (Kineret, other immunomodulatory therapies) and an established rare-disease commercial infrastructure across US and EU, making it directly comparable in target disease areas and business model.
- CSL Behring: CSL Behring markets Haegarda and Berinert, plasma-derived C1 esterase inhibitor products for HAE, directly competing with RUCONEST. As the leading plasma-protein therapeutics company, CSL Behring is a highly relevant direct competitor in Pharming's core market.
- BioCryst Pharmaceuticals: BioCryst markets Orladeyo, an oral prophylactic HAE therapy, directly competing with Pharming's HAE franchise. Its focus on rare-disease oral therapeutics and global commercialization make it a directly comparable competitor.
Broad incumbents
- Takeda Pharmaceutical: Takeda markets Takhzyro and Firazyr for HAE, directly competing with RUCONEST in the same therapeutic area, and operates a global rare-disease commercial organization including rare immunology and genetic disease portfolios.
- BioMarin Pharmaceutical: BioMarin is a leading rare-disease biopharma with a similar business model focused on genetic and ultra-rare conditions, comparable commercial-stage revenue scale, and a pipeline strategy emphasizing orphan indications with high pricing power.
- Recordati: Recordati Rare Diseases division markets treatments for rare conditions and serves as a relevant broad incumbent in the European rare-disease commercial space, with comparable focus on specialty/rare disease therapeutics.
- Alexion / AstraZeneca Rare Diseases: Alexion (now part of AstraZeneca) pioneered the rare-disease commercial model in complement-mediated diseases and serves as a broad incumbent benchmark for rare-disease commercial scale, infrastructure, and orphan-drug portfolio strategy.
Emerging players
- Alnylam Pharmaceuticals: Alnylam develops RNAi therapeutics for rare genetic diseases, including an HAE program, and operates in the same rare-disease commercial space with comparable specialty pharmaceutical infrastructure and orphan-drug pricing economics.
- argenx: argenx develops antibody therapeutics for rare autoimmune diseases, sharing Pharming's rare immunology focus and specialty commercialization model. The company represents a comparable emerging player in rare immune-mediated disease therapeutics.
- Ultragenyx Pharmaceutical: Ultragenyx develops treatments for rare and ultra-rare genetic diseases with a similar orphan-drug commercial model. Its focus on genetic and metabolic rare diseases makes it comparable in pipeline strategy and addressable patient population approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Pharming Group social profiles
Digital presencePharming Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharming Group leadership team
Management profileNumber of profiles
Profiles6 records
Pharming Group subsidiaries and ownership
Company hierarchySubsidiaries3 records
Pharming Group funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharming Group M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharming Group
What does Pharming Group do?
Pharming develops, manufactures, and commercializes protein replacement therapies and precision medicines for rare and ultra-rare immunological and genetic diseases. Its two commercial products are RUCONEST, a recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks, and Joenja (leniolisib), an oral PI3K delta inhibitor for activated PI3K delta syndrome (APDS), with a pipeline extending into primary mitochondrial disease (napazimone/KL1333) and gene therapy for HAE (OTL-105).
Is Pharming Group a public or private company?
Pharming Group is a public company. It is classified as public and is currently operating.
When was Pharming Group founded?
Pharming Group was founded in 1988. It employs 251 to 500 people.
Where is Pharming Group based?
Pharming Group is headquartered in Leiden, Netherlands, in the Europe region.
How does Pharming Group make money?
Three revenue lines are on record. RUCONEST Product Sales are the primary driver. The others are joenja Product Sales and licensing and Royalty Revenue.
Who are Pharming Group's main competitors?
Direct peers on record are Swedish Orphan Biovitrum (Sobi), CSL Behring and BioCryst Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical, BioMarin Pharmaceutical, Recordati and Alexion / AstraZeneca Rare Diseases. Emerging players are Alnylam Pharmaceuticals, argenx and Ultragenyx Pharmaceutical.
Does Pharming Group have an API?
No public API is recorded for Pharming Group.
What industry is Pharming Group in?
Pharming Group's product category is Rare disease biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor). Its NAICS code is 325414 and its SIC code is 2836.